PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
6932980-4	1980	Stimulation by triiodothyronine was maximal at 10(-7) M, and the thyroid effect could be abrogated by the beta 2-adrenergic antagonist butoxamine in equimolar concentrations.	Butoxamine	135-145	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	106-112
6257732-3	1980	The albuterol-mediated inhibition of CFU-E colonies (FV-P-infected) was selectively blocked by butoxamine, a beta-2 antagonist.	Butoxamine	95-105	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	109-115
7387255-1	1980	The cardiovascular effects of intracisternally administered butoxamine, a beta 2-adrenoceptor blocking drug, were studied in both normotensive and acute hypertensive anaesthetized dogs.	Butoxamine	60-70	beta-2 adrenergic receptor	Canis lupus familiaris	74-93
6102965-6	1980	At the 100 ng/ml concentration, DL-propranolol, timolol, metoprolol, practolol, butoxamine, and H35/25 inhibited the angiotensin II potentiation of NS by 83%, 76%, 77%, 59%, 72%, and 41% respectively.	Butoxamine	80-90	angiotensinogen	Rattus norvegicus	117-131
6248606-5	1980	Butoxamine (beta-2 antagonist) was approximately 25 times more potent than practolol (beta-1 antagonist), with KDs of 0.75 microM and 17.5 microM, respectively.	Butoxamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18
26764323-9	2016	The beta2-adrenoceptor antagonists ICI118551 and butoxamine partially suppressed the inhibition of PSE by caffedymine, suggesting that beta2 receptors are involved in inhibition by caffedymine but not by alfrutamide.	Butoxamine	49-59	adrenergic receptor, beta 2	Mus musculus	4-22
41616-11	1979	The ratio of the antagonist potencies of (+/-)practolol and (+/-)butoxamine preferential beta 1- and beta 2-adrenergic antagonists respectively, to block the stimulation of adenylate cyclase was 25 in the cerebellum, compared to 0.5 in the cerebral cortex and 1.6 in the hippocampus.	Butoxamine	60-75	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	89-95
41616-11	1979	The ratio of the antagonist potencies of (+/-)practolol and (+/-)butoxamine preferential beta 1- and beta 2-adrenergic antagonists respectively, to block the stimulation of adenylate cyclase was 25 in the cerebellum, compared to 0.5 in the cerebral cortex and 1.6 in the hippocampus.	Butoxamine	60-75	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	101-107
33812-3	1979	Butoxamine (10 mg/kg) antagonized isoprenaline-induced increases in glucose, lactate and insulin, but not the increases in FFA.	Butoxamine	0-10	insulin	Canis lupus familiaris	89-96
4393214-2	1970	A comparison has been made of the effects of a relatively specific beta(1)-adrenoceptor blocking drug (practolol) and a relatively specific beta(2)-adrenoceptor blocking drug (butoxamine) on myocardial and general haemodynamics in anaesthetized cats.2.	Butoxamine	176-186	adrenoceptor beta 2	Felis catus	140-160
31743979-8	2019	The hippocampal neurogenesis elicited by a 7-day exercise regimen was abolished by a selective inhibitor of beta2-AR, butoxamine.	Butoxamine	118-128	adrenoceptor beta 2	Homo sapiens	108-116
29926197-5	2019	Furthermore, thioperamide, a histamine H3-antagonist, inhibited the increase in skeletal muscle-SNA, and butoxamine, a beta2-antagonist, abolished the increase in skeletal muscle-BF caused by topical application of CAR.	Butoxamine	105-115	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	215-218
28993250-6	2018	iTR hypoalgesia was antagonized by blockade of beta2 and 5HT2A receptors with administration of butoxamine and ketanserin.	Butoxamine	96-106	5-hydroxytryptamine receptor 2A	Rattus norvegicus	47-62
28099883-7	2018	We treated human CSs and CS-derived cells (CDCs) with the beta2-blocker butoxamine (BUT), using either untreated or beta2 agonist (clenbuterol) treated CDCs as control.	Butoxamine	72-82	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	58-63
28464879-7	2017	Butoxamine, a specific beta2-adrenergic antagonist, significantly blocked changes induced by procaterol.	Butoxamine	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	23-28
26738802-5	2016	We found that pretreatment with butoxamine prevented the increases of EE, the mRNA expression of UCP-3, and phosphorylated AMPKalpha that were induced in the gastrocnemius muscle of mice by 10mg/kg FL.	Butoxamine	32-42	uncoupling protein 3 (mitochondrial, proton carrier)	Mus musculus	97-102
39711-7	1978	Superfusion with atenolol (beta 1-adrenoreceptor blocking drug) or butoxamine (beta 2-adrenoreceptor blocking drug) inhibited the pressor response and the tachycardia caused by hypothalamic stimulation.	Butoxamine	67-77	adrenoceptor beta 2	Felis catus	79-100
33979569-2	2021	This study sought to evaluate the effect of the beta-2 adrenergic receptor (beta2-AR) blocker butoxamine on experimental periodontitis in a rat model.	Butoxamine	94-104	adrenoceptor beta 2	Rattus norvegicus	48-74
33979569-2	2021	This study sought to evaluate the effect of the beta-2 adrenergic receptor (beta2-AR) blocker butoxamine on experimental periodontitis in a rat model.	Butoxamine	94-104	adenosine A2a receptor	Rattus norvegicus	76-84
33622325-10	2021	Gene silencing of the beta2-adrenergic receptor in NCI-H292 negated the ability of olodaterol to inhibit IL-8 secretion from both RSV infection and lipopolysaccharide stimulus, as did blocking of the receptor with ICI 118,551 and butaxamine.	Butoxamine	230-240	adrenoceptor beta 2	Homo sapiens	22-47
32909219-8	2020	Furthermore, the beta2-AR antagonist butoxamine significantly reversed the expression of P2X3Rs, the ATP-induced current density, and the number of action potentials of DRG neurons.	Butoxamine	37-47	adenosine A2a receptor	Rattus norvegicus	17-25
31943597-9	2020	Furthermore, immunohistochemical analysis revealed that atenolol, butoxamine and propranolol decreased the number of RANKL- and SOST-positive osteocytes on the compression side.	Butoxamine	66-76	TNF superfamily member 11	Rattus norvegicus	117-122
31943597-9	2020	Furthermore, immunohistochemical analysis revealed that atenolol, butoxamine and propranolol decreased the number of RANKL- and SOST-positive osteocytes on the compression side.	Butoxamine	66-76	sclerostin	Rattus norvegicus	128-132
31003159-7	2019	Butoxamine, a selective beta2-adrenergic receptor antagonist, reversed SALB influence on the activity of PB.	Butoxamine	0-10	adrenergic receptor, beta 2	Mus musculus	24-49
28578076-6	2017	In addition, preinjection of the beta1-AR antagonist, acebutolol, and the beta2-AR antagonist, butoxamine, inhibited the adrenaline-induced increase in PGC-1alpha mRNA levels and the decrease in atrogin-1/MAFbx mRNA levels, respectively.	Butoxamine	95-105	F-box protein 32	Gallus gallus	195-204
26724392-6	2016	This increase was inhibited by a non-selective beta-adrenoceptor antagonist propranolol and by a selective beta3-adrenoceptor antagonist SR59230A, but not by a non-selective alpha-adrenoceptor antagonist phenoxybenzamine, or by a selective beta1-adrenoceptor antagonist atenolol or by a selective beta2-adrenoceptor antagonist butoxamine.	Butoxamine	327-337	adrenoceptor beta 3	Homo sapiens	107-125
26764323-9	2016	The beta2-adrenoceptor antagonists ICI118551 and butoxamine partially suppressed the inhibition of PSE by caffedymine, suggesting that beta2 receptors are involved in inhibition by caffedymine but not by alfrutamide.	Butoxamine	49-59	hemoglobin, beta adult minor chain	Mus musculus	4-9
26426856-6	2015	HIS-induced itch hypersensitivity was attenuated by blockade of sympathetic signaling through guanethidine treatment, and systemic administration of the beta-adrenoceptor antagonist propranolol and the beta2-adrenoceptor antagonist butoxamine, but not on treatment with an alpha-adrenoceptor antagonist phentolamine and a beta1-adrenoceptor antagonist atenolol.	Butoxamine	232-242	adrenoceptor beta 2	Rattus norvegicus	202-220
23718987-10	2013	Based on these in vitro results, we returned to animal testing and observed that the selective beta2-AR antagonist butoxamine reduced nociceptive sensitization in the CRPS model, and that local injection of the selective beta2-AR agonist terbutaline resulted in mechanical allodynia and the production of IL-6 in the cells of the skin.	Butoxamine	115-125	adrenoceptor beta 2	Rattus norvegicus	95-103
25739475-7	2015	Cotreatment with a beta2-adrenergic receptor antagonist, butoxamine, suggests that the effect of terbutaline is mediated by activation of beta2-adrenergic receptors.	Butoxamine	57-67	adrenoceptor beta 2, surface b	Danio rerio	19-44
24965172-10	2014	All of the five RVLM neurons that became depolarized during metoprolol superfusion and hyperpolarized during butoxamine superfusion displayed beta1- and beta2-AR immunoreactivity.	Butoxamine	109-119	adrenoceptor beta 1	Homo sapiens	142-161
25634810-11	2015	Importantly, pancreatic hyperalgesia was markedly attenuated by administration of purinergic receptor antagonist suramin or A317491 or beta2-adrenergic receptor antagonist butoxamine.	Butoxamine	172-182	adrenoceptor beta 2	Rattus norvegicus	135-160
23718987-10	2013	Based on these in vitro results, we returned to animal testing and observed that the selective beta2-AR antagonist butoxamine reduced nociceptive sensitization in the CRPS model, and that local injection of the selective beta2-AR agonist terbutaline resulted in mechanical allodynia and the production of IL-6 in the cells of the skin.	Butoxamine	115-125	interleukin 6	Rattus norvegicus	305-309
22916250-6	2012	A second set of forty mice injected with a single intraperitoneal dose of CCl(4) was treated with saline, 6-hydroxidopamine, Nebivolol or Butoxamine.	Butoxamine	138-148	chemokine (C-C motif) ligand 4	Mus musculus	74-80
23321373-0	2013	Dose effects of butoxamine, a selective beta2-adrenoceptor antagonist, on bone metabolism in spontaneously hypertensive rat.	Butoxamine	16-26	adrenoceptor beta 2	Rattus norvegicus	40-58
23321373-3	2013	In the present study, the dose effects of butoxamine, a selective beta2-adrenoceptor antagonist, on bone metabolism were examined in SHR by analysis of microcomputed tomography, bone histomorphometry, biomechanical testing and plasma biochemistry.	Butoxamine	42-52	adrenoceptor beta 2	Rattus norvegicus	66-84
23321373-6	2013	On the other hand, histomorphometry indices of bone formation and plasma osteocalcin concentration reflecting osteoblastic activity were increased in SHR treated with butoxamine at 0.1 and 1mg/kg, but not at 10mg/kg.	Butoxamine	167-177	bone gamma-carboxyglutamate protein	Rattus norvegicus	73-84
21617579-0	2011	beta2-adrenergic receptor antagonist butoxamine partly abolishes the protection of 100% oxygen treatment against zymosan-induced generalized inflammation in mice.	Butoxamine	37-47	adrenergic receptor, beta 2	Mus musculus	0-25
21617579-9	2011	We found that pretreatment with beta2AR antagonist butoxamine partly abolished the protection of 100% oxygen inhalation.	Butoxamine	51-61	adrenergic receptor, beta 2	Mus musculus	32-39
21207137-5	2011	Pretreatment with propranolol hydrochloride (a non-selective beta-adrenergic receptor blocker) or butaxamine hydrochloride (a selective beta2-adrenergic receptor blocker) occluded the isoproterenol-mediated decrease in blood glutamate levels.	Butoxamine	98-122	adrenoceptor beta 2	Rattus norvegicus	136-161
20637325-6	2010	The epinephrine-enhanced ALP elevation was specifically abolished by an antagonist to beta2-adrenergic receptors (Butoxamine) and by a protein kinase A inhibitor (H89).	Butoxamine	114-124	alkaline phosphatase, placental	Homo sapiens	25-28
19095864-10	2009	In Experiment 2, CSF IL-6 concentrations in the propranolol and butoxamine groups were significantly lower compared with those in the control group (P < 0.01 and P < 0.05 for each group).	Butoxamine	64-74	interleukin 6	Rattus norvegicus	21-25
20566195-10	2010	The decrease in neutrophil adhesion to endothelium following stimulation with interleukin-1 and addition of inotropes is antagonised by the b-blocker butoxamine.	Butoxamine	150-160	interleukin 1 alpha	Homo sapiens	78-91
17869242-6	2007	The selective beta(2)-adrenoceptor antagonist butoxamine blocked this neuroprotective effect of S(+)-clenbuterol.	Butoxamine	46-56	adrenergic receptor, beta 2	Mus musculus	14-34
18202136-8	2008	In porcine aortic endothelial cells, genistein induced the phosphorylation of endothelial nitric oxide synthase and NO production through ERK 1/2, Akt, and p38 MAPK pathways, which was prevented by the concomitant treatment by butoxamine and fulvestrant.	Butoxamine	227-237	nitric oxide synthase 2	Sus scrofa	90-111
19106745-3	2009	METHODS: The beta-adrenoceptor antagonist propranolol, beta1-adrenoceptor antagonist metoprolol, and beta2-adrenoceptor antagonist butoxamine were used to induce apoptosis in PC-2 cells.	Butoxamine	131-141	adrenoceptor beta 2	Homo sapiens	101-119
18814973-11	2008	Importantly, administration of the beta-2 adrenergic receptor agonist terbutaline also caused social withdrawal while administration of the beta-2 adrenergic receptor antagonist butoxamine blocked NE-induced social withdrawal.	Butoxamine	178-188	adrenergic receptor, beta 2	Mus musculus	140-166
17498818-6	2007	In some cases, the selective beta2-AR antagonist butoxamine was administered along with or after morphine.	Butoxamine	49-59	adrenergic receptor, beta 2	Mus musculus	29-37
17498818-12	2007	The chronic administration of butoxamine with morphine reduced or eliminated the normally observed up-regulation of CGRP and SP in spinal cord and DRG tissues.	Butoxamine	30-40	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	116-120
17498818-12	2007	The chronic administration of butoxamine with morphine reduced or eliminated the normally observed up-regulation of CGRP and SP in spinal cord and DRG tissues.	Butoxamine	30-40	tachykinin 1	Mus musculus	125-127
16645459-8	2006	Using the selective beta2-AR antagonist butoxamine, the authors observed a dose-dependent reversal of OIH.	Butoxamine	40-50	adrenergic receptor, beta 2	Mus musculus	20-28
15458278-2	2004	The study found that beta2-AR agonists inhibited the expression of intercellular adhesion molecule-1 (ICAM-1), CD40 and CD14 on monocytes, and that AR agonist activity was antagonized by the selective beta2-AR antagonist, butoxamine.	Butoxamine	222-232	intercellular adhesion molecule 1	Homo sapiens	67-100
15998544-2	2005	The study found that beta2-AR agonists inhibited IL-18 and IL-12 production in monocytes, and that AR agonist activity was antagonized by the selective beta2-AR antagonist, butoxamine.	Butoxamine	173-183	adrenoceptor beta 2	Homo sapiens	21-29
15998544-2	2005	The study found that beta2-AR agonists inhibited IL-18 and IL-12 production in monocytes, and that AR agonist activity was antagonized by the selective beta2-AR antagonist, butoxamine.	Butoxamine	173-183	adrenoceptor beta 2	Homo sapiens	152-160
15458278-2	2004	The study found that beta2-AR agonists inhibited the expression of intercellular adhesion molecule-1 (ICAM-1), CD40 and CD14 on monocytes, and that AR agonist activity was antagonized by the selective beta2-AR antagonist, butoxamine.	Butoxamine	222-232	adrenoceptor beta 2	Homo sapiens	21-29
15908512-10	2005	In contrast, the selective beta2AR antagonists ICI-118,551 and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).	Butoxamine	63-73	adrenoceptor beta 2	Homo sapiens	27-34
15790999-5	2005	Using beta2-specific antagonists (butoxamine and ICI 118551), N-coumaroyldopamine and N-caffeoyldopamine were found to increase cAMP via beta2-adrenoceptors in U937 cells.	Butoxamine	34-44	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	6-11
15790999-5	2005	Using beta2-specific antagonists (butoxamine and ICI 118551), N-coumaroyldopamine and N-caffeoyldopamine were found to increase cAMP via beta2-adrenoceptors in U937 cells.	Butoxamine	34-44	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	137-142
15458278-2	2004	The study found that beta2-AR agonists inhibited the expression of intercellular adhesion molecule-1 (ICAM-1), CD40 and CD14 on monocytes, and that AR agonist activity was antagonized by the selective beta2-AR antagonist, butoxamine.	Butoxamine	222-232	intercellular adhesion molecule 1	Homo sapiens	102-108
15458278-2	2004	The study found that beta2-AR agonists inhibited the expression of intercellular adhesion molecule-1 (ICAM-1), CD40 and CD14 on monocytes, and that AR agonist activity was antagonized by the selective beta2-AR antagonist, butoxamine.	Butoxamine	222-232	adrenoceptor beta 2	Homo sapiens	201-209
12596892-6	2002	However, in the presence of 3 x 10(-4) M atenolol, 10(-4) M butoxamine and 10(-6) M phentolamine to block the beta1-, beta2- and a-adrenoceptor effects, respectively, Schild regression analysis carried out for bupranolol against fenoterol gave pA2 values of 5.80.	Butoxamine	60-70	beta-2 adrenergic receptor	Cavia porcellus	110-143
12883327-7	2003	Similarly, the incubation with the beta(2)-adrenoceptor antagonist butoxamine (50 micromol/L) did not prevent vasorelaxation.	Butoxamine	67-77	adrenoceptor beta 2	Rattus norvegicus	35-55
15145612-2	2004	All responses by these stimulations were antagonized by the selective beta 2-adrenergic receptor (AR) antagonist, butoxamine, but not by alpha 1-, alpha 2- and beta 1-AR antagonists.	Butoxamine	114-124	adrenoceptor beta 2	Homo sapiens	70-96
11885748-4	2001	The combination of the selective beta1-adrenoceptor antagonist (+/-)-atenolol (100 microM), and the selective beta2-adrenoceptor antagonist (+/-)-butoxamine (100 microM), produced a 2 and 6 fold rightward shift of the concentration-response curves for (+/-)-terbutaline and (+/-)-fenoterol respectively, without depressing the maximal responses.	Butoxamine	140-156	beta-2 adrenergic receptor	Cavia porcellus	110-128
11885748-6	2001	In the presence of (+/-)-atenolol and (+/-)-butoxamine, however, the non-selective beta1, beta2- and beta3-adrenoceptor antagonist (+/-)-bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for (+/-)-terbutaline and (+/-)-fenoterol.	Butoxamine	38-54	beta-3 adrenergic receptor	Cavia porcellus	101-119
11729357-4	2001	In the presence of both atenolol and butoxamine, the nonselective beta(1)-, beta(2)- and beta(3)-adrenoceptor antagonist (+/-)-bupranolol (10(-5)-10(-4) mol/l) caused a concentration-dependent rightward shift of the concentration-response curves for (+/-)-pindolol.	Butoxamine	37-47	beta-3 adrenergic receptor	Cavia porcellus	89-109
10924081-4	2000	Results from using an in vitro tissue bath technique indicated that propranolol and preferential beta(2)-adrenoceptor antagonists (ICI-118,551 and butoxamine), in a concentration-dependent manner, blocked the relaxation induced by nicotine (100 microM) without affecting the relaxation elicited by transmural nerve stimulation (TNS, 8 Hz).	Butoxamine	147-157	adrenoceptor beta 2	Homo sapiens	97-117
11138729-3	2000	However, a combination of the selective beta1-adrenoceptor antagonist atenolol (100 microM) and the selective beta2-adrenoceptor antagonist butoxamine (100 microM) produced only small rightward shifts in the concentration-response curves of carteolol in the gastric fundus (pD2 = 4.91, intrinsic activity = 0.94).	Butoxamine	140-150	beta-2 adrenergic receptor	Cavia porcellus	110-128
11138729-4	2000	In the presence of both atenolol (100 microM) and butoxamine (100 microM), the non-selective beta1-, beta2- and beta3-adrenoceptor antagonist (+/-)-bupranolol (10-100 microM) caused a concentration-dependent right-ward shift of the concentration-response curves for carteolol in the guinea pig gastric fundus.	Butoxamine	50-60	beta-2 adrenergic receptor	Cavia porcellus	93-130
9881581-6	1998	The selective beta2-adrenoceptor antagonist butoxamine (10 microM) slightly reduced the cardiac response to 50 microg, but not to 100 microg of venom.	Butoxamine	44-54	adrenoceptor beta 2	Rattus norvegicus	14-32
10629867-3	1999	In the presence of propranolol (1 microM) or atenolol (100 microM) plus butoxamine (100 microM), bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for catecholamines and beta 3-adrenoceptor agonists.	Butoxamine	72-82	beta-3 adrenergic receptor	Cavia porcellus	217-236
7686438-5	1993	The effect on CD23 expression of salbutamol and fenoterol, but not of IL-4, was blocked in the presence of D,L-propranolol (1 microM) or butoxamine (1 microM).	Butoxamine	137-147	Fc epsilon receptor II	Homo sapiens	14-18
9533821-7	1997	However, in the presence of 3 x 10(-4) M atenolol, 10(-4) M butoxamine and 10(-6) M phentolamine to block the beta1-, beta2- and alpha-adrenoceptor effects, respectively, Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 5.77 and 5.97, respectively.	Butoxamine	60-70	beta-2 adrenergic receptor	Cavia porcellus	110-147
7600375-6	1995	The potentiating effect of salbutamol on IgE production was blocked by two antagonists of beta 2-adrenoceptor, namely butoxamine and D,L-propranolol, suggesting a beta-adrenoceptor-mediated event.	Butoxamine	118-128	adrenoceptor beta 2	Homo sapiens	90-109
7777207-2	1995	The peak release of ATP 5 min after 1 microM isoprenaline was inhibited by 1 microM propranolol and 1 microM butoxamine, but not by 1 microM atenolol, showing that the ATP release is due to stimulation of the presynaptic beta 2-adrenoceptor by isoprenaline.	Butoxamine	109-119	beta-2 adrenergic receptor	Cavia porcellus	221-240
7958736-6	1994	In the presence of butoxamine, a selective beta 2-adrenoceptor inhibitor, but not metoprolol, a selective beta 1-adrenoceptor inhibitor, SNP still inhibited isoproterenol-relaxation.	Butoxamine	19-29	adrenoceptor beta 2	Rattus norvegicus	43-62
8909778-5	1996	After addition of 1 microM butoxamine, a beta 2-adrenoceptor antagonist, the tissues from stressed rats were subsensitive to adrenaline.	Butoxamine	27-37	adrenoceptor beta 2	Rattus norvegicus	41-60
8385784-5	1993	The enhanced sensitivity to ISO was abolished by butoxamine (a selective beta 2-adrenoceptor antagonist) and accompanied by a marked increase in the pA2 value of this antagonist.	Butoxamine	49-59	adrenoceptor beta 2	Rattus norvegicus	73-92
34220541-12	2021	Leptin levels recovered following butoxamine administration.	Butoxamine	34-44	leptin	Rattus norvegicus	0-6
1970836-1	1990	Employing propranolol as a non-selective beta-blocker, atenolol, acebutolol and metoprolol as selective beta 1-blockers, butoxamine as a selective beta 2-blocker, labetalol as an alpha- and beta-blocker, and phentolamine as an alpha-blocker, we compared the effects of these adrenoceptor-blocking agents to reduce the degree of the myocardial injury induced by epinephrine in mice.	Butoxamine	121-131	hemoglobin, beta adult minor chain	Mus musculus	147-153
8096259-5	1993	Computer analysis of inhibition of [3H]-DHA binding by atenolol, butoxamine and ICI 118,551 gave a beta 1: beta 2-adrenoceptor ratio of approximately 65:35.	Butoxamine	65-75	adrenoceptor beta 2	Sus scrofa	107-126
34220541-15	2021	Conversely, recovery of RANKL expression was observed in IH-exposed rats administered with butoxamine.	Butoxamine	91-101	TNF superfamily member 11	Rattus norvegicus	24-29
2877082-6	1986	Butoxamine (5 X 10(-6) M), a beta-2 antagonist, but not atenolol (5 X 10(-6) M), a beta-1 antagonist, blocked the epinephrine-induced increase in cell-mediated cytotoxicity.	Butoxamine	0-10	hemoglobin, beta adult minor chain	Mus musculus	29-35
2839667-7	1988	However, footshock stress induces a large increase in the pacemaker beta-2 adrenoceptor affinity for butoxamine (11.48-fold, pA2 value).	Butoxamine	101-111	adrenoceptor beta 2	Rattus norvegicus	68-87
2866208-3	1985	The beta 1-adrenergic receptor was responsible for mediation of these changes with both agonists since the effects of either agonist were prevented when a 10 mg/kg dose of the beta 1-antagonist, atenolol, was injected 20 min prior to the agonist, and the increase induced by either agonist was not prevented when the beta 1-adrenergic antagonist, butoxamine, was given prior to each agonist.	Butoxamine	347-357	adrenoceptor beta 1	Rattus norvegicus	4-30
2858837-3	1985	Both salbutamol (beta 2-agonist) and butoxamine (beta 2-antagonist) inhibited aqueous humor formation and aqueous humor outflow to an equal extent.	Butoxamine	37-47	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	49-55
6704473-6	1984	Treatment with propranolol or with butoxamine, a nonspecific beta- and a specific beta 2-adrenergic receptor blocker, respectively, antagonized the testicular hyposensitivity to hCG induced by stress.	Butoxamine	35-45	adrenoceptor beta 2	Rattus norvegicus	61-108
6151668-6	1984	Additional experiments were carried out with butoxamine, a selective beta 2-adrenoceptor antagonist, (1.5 and 3.0 g/kg of food) to determine its effect on intake of 0.25 M NaCl solution.	Butoxamine	45-55	adrenoceptor beta 2	Rattus norvegicus	69-88
6144326-7	1984	In accordance with the influence of the agonists, the beta 2-antagonist butoxamine, but not the beta 1-antagonists atenolol, metoprolol and practolol, reversed the catecholamine action on sterol synthesis.	Butoxamine	72-82	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	54-60
6330618-2	1984	This protective action of TRH was blocked by pretreatment with the beta-adrenergic antagonist propranolol (5 mg/kg), or by prior administration of the cardioselective beta 1-antagonist, metoprolol (5 mg/kg), but not by pretreatment with the beta 2-selective antagonist, butoxamine (5 mg/kg).	Butoxamine	270-280	thyrotropin releasing hormone	Mus musculus	26-29
6704473-6	1984	Treatment with propranolol or with butoxamine, a nonspecific beta- and a specific beta 2-adrenergic receptor blocker, respectively, antagonized the testicular hyposensitivity to hCG induced by stress.	Butoxamine	35-45	hypertrichosis 2 (generalised, congenital)	Homo sapiens	178-181
6197312-3	1983	Propranolol 0.1 and 1.0 microM and butoxamine 10 and 100 microM significantly antagonized the effects of fenoterol 0.1 microM on SRS-A and histamine at concentrations which affect (beta 2-adrenoceptors, while atenolol 0.1 to 10 microM showed no antagonism at concentrations which affect beta 1-adrenoceptors.	Butoxamine	35-45	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	181-187
6141003-1	1984	Butoxamine, a beta 2-adrenergic blocking agent, which temporarily blocks the G1-S transition of human bone marrow granulocyte precursors in vitro, was used in vivo together with 1-beta-D-arabinofuranosylcytosine (ara-C) in mice.	Butoxamine	0-10	histocompatibility 2, O region beta locus	Mus musculus	12-20
6579847-5	1983	Butoxamine, a somewhat selective beta 2-adrenergic antagonist drug, also produced a significant inhibition of the effects of PGE2 on CFU-E in murine marrow cultures.	Butoxamine	0-10	hemoglobin, beta adult minor chain	Mus musculus	33-39
6257884-2	1981	Beta-1 and beta-2 adrenergic receptor blockade were produced with atenolol and butoxamine, respectively.	Butoxamine	79-89	adrenoceptor beta 2	Homo sapiens	11-37
6257884-10	1981	In contrast, beta-2 receptor blockade with butoxamine (20 micrograms/kg/min) did not alter the renin secretion response to renal nerve stimulation.	Butoxamine	43-53	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	13-19
6257884-11	1981	This dose of butoxamine decreased the renal vasodilator response to intrarenal isoproterenol by 73%, thus demonstrating significant beta-2 receptor blockade.	Butoxamine	13-23	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	132-138
6259042-3	1980	In addition, the beta 2-selective antagonist butoxamine was slightly more potent in inhibiting the isoproterenol-stimulated fat cell enzyme than the cardioselective beta-blocking agent practolol.	Butoxamine	45-55	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	17-23